Second, we chose representative STAT3 target genes and relevant JAK-STAT pathways for pharmacological experimental validation, but we did not test the inhibitory effects of FHB on MAPK, PI3K/Akt, NF-κB, HIF-1α, and other inflammatory pathways associated with vitiligo and predicted network pharmacological results. The gene discussed is STAT3; the disease is vitiligo.